In April 2017 Integrated Pathology Partnerships issued the following Modern Slavery and Human Trafficking Statement:
Modern slavery and human trafficking can take many forms including the trafficking of people, forced labour, servitude and slavery. Labco UK Group Limited (the “Company”) fully supports the Government’s objectives to eradicate modern slavery and human trafficking and is strongly committed to ensuring our supply chains and business activities are free from ethical and labour standards abuse.
The Company is part of the Synlab Group, whose ultimate parent is Synlab Limited. The Synlab group of companies is a market leader in medical diagnostic services for healthcare professionals, healthcare organisations and the pharmaceutical industry.
Integrated Pathology Partnerships (“iPP”) works in partnership with the NHS to deliver transformed pathology testing services in the UK. iPP’s hospital partnerships including Southwest Pathology Services (“SPS”), Pathology First and the Christie Pathology Partnership (“CPP”), now conduct more than 25 million tests per annum across all pathology disciplines including Clinical Chemistry, Haematology, Immunology, Microbiology and Cellular Pathology, and employs over 650 staff across eight sites in the UK.
Synlab Laboratory Services (“SLS”) provides food, drug and alcohol testing from two main laboratory sites. It employs 160 staff who either work at one of these laboratories or work remotely attending client sites to administer and collect samples.
Labco Diagnostics UK supplies renal pathology testing, carrying out more than 40 different types of tests across the pathology disciplines; Clinical Chemistry, Haematology and Serology (Hepatitis B and C screening). It has one laboratory location and employs 7 staff.
Synlab UK specialises in providing end-to-end services for the diagnosis of Latent Tuberculosis Infection (LTBI), and is experienced in carrying out a broad range of pathology services in support of clinical trials.
Synlab UK’s preferred partnerships enables it to source innovative tests and to find ways to introduce these tests both to private physicians and clinics, as well as to NHS organisations. Synlab UK has developed a very wide portfolio of molecular and genetic diagnostic tests and currently provides specialist cancer testing, non-invasive prenatal testing and various women’s health testing.
The Company is a wholly-owned subsidiary of Synlab Limited, which is the ultimate parent of the Synlab group of companies, the European leader in delivery of high quality pathology testing and imaging services. Further details about what we do can be found on our website.
The Policy and its implementation
We are committed to ensuring that there is no form of modern slavery or human trafficking present in our supply chains or in any part of our business. Our Modern Slavery and Human Trafficking Policy reflects our commitment to acting ethically and with integrity in all our business relationships and to implementing and enforcing effective systems and controls to ensure that slavery and human trafficking is not taking place anywhere in the Company or our supply chain.
The new policy ensures all workers have a good understanding of how to prevent exploitation and human trafficking within our business and our supply chain. We have adjusted our Resourcing, Grievance and Whistleblower Policies and our Code of Ethics Policy which all new staff are required to sign before commencement, to include reference to our stance in this area.
We have written to all suppliers providing services to the Company businesses to make clear our expectation of equal commitment to the prevention of modern slavery and human trafficking within their own businesses and supply chains. We have included specific prohibitions against the use of forced, compulsory or trafficked labour or anyone held in slavery or servitude (whether adults or children), and we expect that our suppliers will hold their own suppliers to the same high standards. If there is a failure by a supplier to meet the standards set out in this letter, in the first instance, the Company would seek to give support and guidance to tackle the issue. The Company intends to make provision in future contracts to identify failure to meet the expected standards as a breach of contract which, may result in the termination of our relationship with any supplier at fault.
Our due diligence checks ensure that the Company is compliant with all relevant legislation and we continue to review our policies and processes to ensure compliance is maintained.
All staff recruited into the Company undergo relevant pre-employment checks. The Company checks the identity and eligibility to work in the UK of all candidates and ensure a Disclosure Barring Service (“DBS”) check is completed if the role involves working closely with patients, vulnerable adults or children. The Company also pay all staff the National Living Wage or above.
The Company intends to take further steps to support our employees to understand and respond to modern slavery and human trafficking.
Throughout the coming year the Company commits to ensuring that all employees have access to training with respect to modern slavery & human trafficking which will provide the latest information and the skills to ensure that employees understand the relevant Company processes and can identify potential warning signs of modern slavery & human trafficking.
Review and next steps
The Company will review its actions in relation to the Modern Slavery and Human Trafficking Policy annually and will monitor the completion of training of both existing and new employees. We will develop a Supplier Code of Conduct which will be issued out to all suppliers and include the ongoing requirement for monitoring respective supply chains.
This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes the Company’s Modern Slavery & Human Trafficking Statement for the financial year 2016/2017. This statement has been approved and authorised by:
Name: Stuart Quin
Position: Chief Executive, Synlab UK
Date: 28 April 2017